Physicians' Academy for Cardiovascular Education

Optimizing RAAS inhibition in Heart Failure: Novel treatment considerations for the managament of hyperkalemia

Meeting Impression: Optimizing RAAS inhibition in Heart failure: Novel treatment considerations for the management of hyperkalemia

News - May 24, 2016
Optimizing RAAS inhibition in Heart failure: Novel treatment considerations for the management of hyperkalemia

During the ESC Heart Failure Congress 2016, held in Florence PACE-CME organised a satellite symposium that elaborated on beneficial and unwanted effects of RAAS inhibition in heart failure. Hyperkalaemia is a common comorbid condition, which is often the reason that patients receive suboptimal treatment. Also when potassium levels are high, a patient still benefits from RAAS-inhibiting treatment.

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure

News - May 22, 2016
he future of HF management: How does potassium binding fit within pharmacological treatment of heart failure

Dickstein started off outlining the concept that HF is not a disease but a syndrome with multiple causes and converges many symptoms, making it a very large and heterogeneous population. This population is rapidly growing and prevalence estimates depend on how HF is defined

Hyperkalaemia: novel treatment strategies to manage potassium levels in heart failure

News - May 22, 2016
Hyperkalaemia: novel treatment strategies to manage potassium levels in heart failure

Several therapeutic options exist for hyperkalaemia. Insulin, beta-adrenergic agonists and sodium bicarbonate are used in acute situations. In case of very high potassium levels, dialysis can be done.

RAAS inhibition in heart failure: corner stone of therapy & potassium homeostasis

News - May 22, 2016
RAAS inhibition in heart failure: corner stone of therapy & potassium homeostasis

Prof. Zannad explained the implementation of RAAS inhibitors (RAASi) for the treatment of HF in clinical practice and their clinical impact. He showed that RAASi are frequently omitted or discontinued in clinical practice, although HF guidelines strongly recommend the use of RAASi for several indications.